Shanghai Auzone
- Biotech or pharma, therapeutic R&D
We have developed an edaravone oral tablet. The BE clinical study for ALS treatment will start in US in Q3 2023 and NDA will be applied in Q1 2024. The phase 3 study for AIS treatment has started in Q1 2023 and will be completed in China in Q1 2024.
Address
SuzhouJiangsu
China
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}